We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Cizzle Biotechnology Holdings Plc | CIZ | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.70 | 07:46:26 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.70 | 1.70 | 1.70 | 1.70 | 1.70 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 03/4/2024 06:17 by geoff98 Don't disagree @dplewis. The silver lining, in my view, is that they have made the announcement & hopefully are clear that if they try to get too clever with their carefully worded comments again, PIs will be there to hold them to account. Everyone is much clearer now that commercialisation is, in fact, NOT imminent. The test is still groundbreaking & potentially a huge money spinner imo, but investors can now make their decisions on a slightly more realistic basis. Hence, I would say we have taken a step forward. Re the commercialisation, my opinion is that they don't have the required expertise within the company & are being blown around by the prevailing winds as a result. I'm hopeful (but by no means certain) that they can get this over the line by hook or by crook. I'm less hopeful that they will not try to screw PIs, so I, for one, will continue to watch every move they make as closely as possible. |
Posted at 27/3/2024 10:54 by geoff98 Some good work going on from some contributors over on the other boards. Any genuine investors should consider following their example. The only way to hold the company to account is to take the initiative. PIs have very little control, however the one thing they can do is kick up an almighty stink when things aren't being done properly. Good stuff, imo. |
Posted at 11/3/2024 15:10 by oapknob1 We are delighted to congratulate Bill Behnke on his appointment to the Conquer Cancer Board of Directors. Bill leads Cizzle Biotechnology's business development in the USA and was responsible for identifying and facilitating the Company's deal with CorePath Laboratories, a full-service cancer reference laboratory, to develop and offer Cizzle Biotechnology plc's proprietary early-stage lung cancer test in the USA. Conquer Cancer, the ASCO Foundation, funds research for every cancer, to help every patient, everywhere. Since 1984, its Grants & Awards program has awarded more than $182 million in funding through over 8,700 grants and awards to medical students, residents, fellows, scientists, and oncologists in 88 countries. Bill has decades of success in delivering major revenues and raising capital from VC, PE and private investors. He continues to promote support for major cancer charities and advocacy groups such as the Leukemia and Lymphoma Society, Conquer Cancer, the ASCO Foundation, the AYA Cancer Foundation and the South Texas Blood and Tissue Center.His appointment to the Conquer Cancer Board will enable Bill to further expand his current programme with Cizzle Biotechnology plc, providing access to healthcare corporations, hospitals, clinicians and key opinion leaders involved in driving early-stage cancer detection. Learn more about this great organisation at: www.conquer.org https://brnw.ch/21wH |
Posted at 28/1/2024 13:43 by bollockks Hitman my last message you need to get urgent help something not wired up rightSeriously def get help this is not normal Don’t bother replying never coming back here not important for me or my investing strategy so take my advise Gla all investors in any company |
Posted at 28/1/2024 09:49 by edcremin Yeah, it must be hitman, what kind of idiot holds here if he thinks there is going to be a fund raise at 1p.. Jiba, what kind of idiot takes that as a genuine opinion.. investors should formulate their own opinions. Watch the video in the header, read the RNS, or listen to idiots on here and miss out on the opportunity of a lifetime, which doesn't bother me (trend is up) |
Posted at 24/1/2024 21:26 by bigbarry One for pure gamblers, not for investors.Funding next |
Posted at 15/1/2024 17:49 by pennyfalls Shame isn’t it.Message boards used to be a source of good information and views between investors, but such is the modern age and self-involved children needing attention. Serves no purpose but ruins potentially good conversations. I suppose that’s where he gets his power kick. |
Posted at 27/11/2023 22:19 by oapknob1 Variation to GBP500,000 Loan FacilityPursuant to its facility agreement with E3 Fund share price (the "Investor") entered into on 20 September 2022 ("Facility") and amended on 21 April 2023, the Company and the Investor are pleased to announce they have agreed to vary the terms of the Facility to enable the Subscription to proceed at a premium to the fixed repayment price of the Facility of 1.8p per share.The Facility has been extended until 8 December 2024 and will be drawable in tranches of not less than GBP100,000 as requested by the Company or the Investor. The first drawdown will be made available to the Company following Shareholder Approval at the Company's next General Meeting to allot a further 23,809,524 new Ordinary Shares. Repayment of the Facility is to be by way of issue and allotment of new Ordinary Shares in the capital of the Company at a new fixed price equal to the Issue Price of 2.1p per share ("Facility Shares"). |
Posted at 22/10/2023 11:50 by secretsqu What pumpers are you referring to?If you take a look at the last 10 days there have been 25 posts. 9 from investors and 16 from you. 4 of the 9 posts were responses to your idiotic rhetoric. Show me any one of those 9 posts that ramped or pumped the share price of this share!Then compare that with your ramptastic posts on APTA.You're not very bright.Case closed |
Posted at 14/9/2023 08:49 by oapknob1 Item 1.01. Entry into a Material Definitive Agreement. As previously reported by Murphy Canyon Acquisition Corp., a Delaware corporation (the "Company"), on Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission (the "SEC") on November 8, 2022, November 14, 2022, January 30, 2023 and May 11, 2023, the Company entered into an Agreement and Plan of Merger, dated as of November 8, 2022, as amended on January 27, 2023 and May 11, 2023 (as amended, the "Merger Agreement"), with Conduit Merger Sub, Inc., a Cayman Islands exempted company and wholly-owned subsidiary of the Company (the "Merger Sub"), and Conduit Pharmaceuticals Limited, a Cayman Islands exempted company ("Conduit"), pursuant to which, among other matters, subject to the terms and conditions therein, the Company intends to consummate its initial business combination with Conduit (the "Business Combination"). The Company following the Business Combination is referred to herein as "New Conduit." In connection with the transactions contemplated by the Merger Agreement, on September 13, 2023, the Company entered into a Subscription Agreement (the "Subscription Agreement") with Nirland Limited, a Guernsey company (the "Private Placement Investor"), which is in lieu of, and on substantially similar terms as, the previously entered into private placement for $27 million. Pursuant to the Subscription Agreement, the Private Placement Investor has agreed to purchase $20 million (the "Private Placement") units of the Company (the "Units"), with each Unit consisting of (i) one share of the Company's common stock and (ii) one warrant to purchase one share of the Company's common stock (each, a "Warrant"), for a purchase price of $10.00 per Unit (the "Purchase Price") in the Private Placement. The Subscription Agreement contains registration rights, pursuant to which within fifteen (15) business days after the closing of the Private Placement, the Company will use reasonable best efforts to file with the SEC a registration statement registering the resale of shares of common stock included in the Units and the shares of common stock issued and issuable upon exercise of the Warrants. The closing of the Private Placement is conditioned on there not being a suspension of the qualification of common stock for offering or sale or trading in any jurisdiction, or the initiation or threatening of any material legal proceeding, no legal prohibitions to consummate the Business Combination, and all conditions precedent to the closing of the Business Combination set forth in the Merger Agreement having been satisfied or waived. The Warrant will be exercisable for a period of five years after the completion of the Business Combination and will have an exercise price of $11.50 per share, subject to adjustment as set forth in the Warrant for stock splits, stock dividends, recapitalizations and similar customary adjustments. The Private Placement Investor may exercise each Warrant on a cashless basis if the shares of common stock underlying the Warrants are not then registered pursuant to an effective registration statement. The Private Placement Investor has contractually agreed to restrict its ability to exercise the Warrants such that the number of shares of the common stock held by the Private Placement Investor and its affiliates after such exercise does not exceed the beneficial ownership limitation set forth in the Warrant which may not exceed 4.99% of then issued and outstanding shares of the Company's common stock. On September 13, 2023, St George Street Capital ("St George Street"), an existing holder of Conduit's ordinary shares, sold 78 of the ordinary shares of Conduit held by it to the Private Placement Investor in a transaction unrelated to the Private Placement. As a result, St George Street is anticipated to hold approximately 4,749,313 shares of New Conduit common stock following the Business Combination, which is anticipated to be approximately 7.3% of the issued and outstanding shares of common stock of New Conduit. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
